期刊
TRENDS IN CANCER
卷 6, 期 6, 页码 489-505出版社
CELL PRESS
DOI: 10.1016/j.trecan.2020.02.020
关键词
-
类别
资金
- Precision Oncology Ireland - Science Foundation Ireland Strategic Partnership Programme [18/SPP/3522]
- SFI Starting Investigator Grant [15/SIRG/3528]
- EU H2020 MSCA [RISE-734749]
- Canada Research Chairs program
- Science Foundation Ireland (SFI) [15/SIRG/3528] Funding Source: Science Foundation Ireland (SFI)
Chemoresistance is a major factor driving tumour relapse and the high rates of cancer-related deaths. Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival. One emerging mechanism of chemoresistance is the tumour cell secretome (TCS), an array of protumorigenic factors released by tumour cells. Chemotherapy exposure can also alter the composition of the TCS, known as therapy-induced TCS, and can promote tumour relapse and the formation of an immunosuppressive tumour microenvironment (TME). Here, we outline how the TCS can protect cancer cells from chemotherapy-induced cell death. We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据